Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel DiseasesErwin Dreesen, Séverine Vermeire, Bram Verstockt et al.|Clinical Gastroenterology and Hepatology|2018Cited by 158
Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission RatesBram Verstockt, Marc Ferrante, Erwin Dreesen et al.|Journal of Crohn s and Colitis|2019Cited by 123
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn’s Disease Who Failed Biologic Therapies: A National Cohort StudyClaire Liefferinckx, Séverine Vermeire, Dirk Staessen et al.|Journal of Crohn s and Colitis|2019Cited by 121
Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivationHerbert Nar, Paul Declerck, Jean–Marie Stassen et al.|Journal of Molecular Biology|2000Cited by 95
Influence of early adalimumab serum levels on immunogenicity and long‐term outcome of anti‐TNF naive Crohn's disease patients: the usefulness of rapid testingBram Verstockt, Marc Ferrante, Gitte Moors et al.|Alimentary Pharmacology & Therapeutics|2018Cited by 74